Can Senhwa’s CX-5461 finally turn cold tumors hot in immunotherapy’s toughest challenge?

Can Senhwa’s CX-5461 finally turn cold tumors hot in immunotherapy’s toughest challenge?

Senhwa Biosciences Inc. and BeOne Medicines have signed a clinical supply agreement to explore a novel drug combination aimed at treating hard-to-reach cancers. The collaboration will test Senhwa’s lead compound Pidnarulex (CX-5461), a G-quadruplex stabilizer, in combination with BeOne’s PD-1 inhibitor tislelizumab. The Phase 1b/2a clinical trial will enroll patients with advanced solid tumors, including […]